Short Interest in Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Declines By 86.6%

Basilea Pharmaceutica AG (OTCMKTS:BPMUF) was the recipient of a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 2,100 shares, a decline of 86.6% from the February 28th total of 15,700 shares. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is currently 21.0 days. Approximately 0.0% of the shares of the company are short sold.

Basilea Pharmaceutica Stock Performance

Basilea Pharmaceutica stock remained flat at $54.00 during midday trading on Wednesday. The stock’s 50 day moving average is $52.90 and its 200-day moving average is $52.59. Basilea Pharmaceutica has a 52-week low of $38.60 and a 52-week high of $54.00. The company has a debt-to-equity ratio of 5.70, a current ratio of 4.10 and a quick ratio of 3.27.

Basilea Pharmaceutica Company Profile

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.